And now Malaysia is looking to grab a bigger piece of the global medical device industry. The New Straits Times reports that INFO Kinetics, a Malaysian research laboratory, and South Korea's Clinical Trial Centre for Medical Devices of Yeungnam University Hospital have agreed to develop the first major medical devices clinical trials center in Malaysia's Northern Corridor Economic Region.
The Taiwanese government has recently been touting the country as a perfect environment for medical device companies targeting emerging markets, and Swissray International, maker of imaging devices, would seem to agree. The Switzerland-headquartered company is planning to expand into the country.
Lundbeck has opened its first manufacturing plant in China as it chases competitors that have beat it there with drugmaking facilities and joint ventures.
In a move that flies in the face of the trend of drugmakers flocking to China, Indian API maker Orchid Chemicals & Pharmaceuticals is selling its joint venture interest there and retreating back to India.
Mindray Medical, China's largest medical device outfit, has had a rough couple days, posting a 4.2% net income drop in the third quarter and getting pilloried by shareholders as a result.
Sigma-Aldrich is tapping the South Korean market with a deal to provide development support for active pharmaceutical ingredients for new non-steroidal anti-inflammatory drugs from a South Korean company.
Bayer HealthCare has struck a deal with a Russian drug manufacturer that will allow it to start producing products in a country that is considered one of the best bets for future growth.
In the face of pricing pressures at home and abroad, Medtronic ($MDT) needs to focus not only on the clinical value its devices provide, but also the economic benefit, CEO Omar Ishrak said.
No question, Big Pharma is feeling a bit persecuted in India these days. And now, multinational drugmakers have one more reason to fear. The country's patent appeals board has yanked Roche's ($RHHBY) patent on Pegasys, a hepatitis C drug that's been on the market there since 2006.
The market for clinical trials in India is worth about $1.5 billion and predicted to grow hand-over-fist, but if the country doesn't set straight its regulatory policies, it stands to lose ground to other emerging players, The Times of India opines